Interpretation of Steroid Biomarkers in 21-Hydroxylase Deficiency and Their Use in Disease Management
The Journal of Clinical Endocrinology & Metabolism · 18.08.2023 · 108 (9) · 2154-2175
DOI: 10.1210/clinem/dgad134 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 23.03.2023. Verfasst von Kyriakie Sarafoglou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Endocrinology, University of Minnesota Medical School, Minneapolis, MN 55454, USA. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The most common form of congenital adrenal hyperplasia is 21-hydroxylase deficiency (21OHD), which in the classic (severe) form occurs in roughly 1:16 000 newborns worldwide. Lifelong treatment consists of replacing cortisol and aldosterone deficiencies, and supraphysiological dosing schedules are typically employed to simultaneously attenuate production of adrenal-derived androgens. Glucocorticoid titration in 21OHD is challenging as it must balance the consequences of androgen excess vs those from chronic high glucocorticoid exposure, which are further complicated by interindividual variability in cortisol kinetics and glucocorticoid sensitivity. Clinical assessment and biochemical parameters are both used to guide therapy, but the specific purpose and goals of each biomarker vary with age and clinical context. Here we review the approach to medication titration for children and adults with classic 21OHD, with an emphasis on how to interpret adrenal biomarker values in guiding this process. In parallel, we illustrate how an understanding of the pathophysiologic and pharmacologic principles can be used to avoid and to correct complications of this disease and consequences of its management using existing treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Pediatric Endocrinology, University of Minnesota Medical School, Minneapolis, MN 55454, USA.
- Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN 55455, USA.
- Department of Pediatrics, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA.
- Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA.
- Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, 80336 Munich, Germany.
- Department of Pediatrics, Amalia Children's Hospital, Radboud University Medical Center, 6500 HB, Nijmegen, The Netherlands.
ORCID-Profile: Kyriakie Sarafoglou, Deborah P Merke, Nicole Reisch, Hedi Claahsen-van der Grinten, Henrik Falhammar, Richard J Auchus
Zitieren
APA
Sarafoglou, K., Merke, D. P., Reisch, N., Claahsen-van der Grinten, H., Falhammar, H., & Auchus, R. J. (2023). Interpretation of Steroid Biomarkers in 21-Hydroxylase Deficiency and Their Use in Disease Management. The Journal of Clinical Endocrinology & Metabolism, 108(9), 2154-2175. https://doi.org/10.1210/clinem/dgad134
Vancouver
Sarafoglou K, Merke DP, Reisch N, Claahsen-van der Grinten H, Falhammar H, Auchus RJ. Interpretation of Steroid Biomarkers in 21-Hydroxylase Deficiency and Their Use in Disease Management. The Journal of Clinical Endocrinology & Metabolism. 2023;108(9):2154-2175. doi:10.1210/clinem/dgad134
BibTeX
@article{Sarafoglou2023,
author = {Sarafoglou, Kyriakie and Merke, Deborah P and Reisch, Nicole and Claahsen-van der Grinten, Hedi and Falhammar, Henrik and Auchus, Richard J},
title = {Interpretation of Steroid Biomarkers in 21-Hydroxylase Deficiency and Their Use in Disease Management},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {9},
pages = {2154--2175},
doi = {10.1210/clinem/dgad134}
}
EUVIMED